Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.

ABSTRACT: The treatment landscape of multiple myeloma (MM) has evolved considerably with the FDA-approval of at least 15 drugs over the past two decades. Together with the use of autologous stem cell transplantation, these novel therapies have resulted in significant survival benefit for patients with MM. In particular, our improved understanding of the BM and immune microenvironment has led to the development of highly effective immunotherapies that have demonstrated unprecedented response rates even in the multiple refractory disease setting. However, MM remains challenging to treat especially in a high-risk setting. A key mediator of therapeutic resistance in MM is the bone marrow (BM) microenvironment; a deeper understanding is necessary to facilitate the development of therapies that target MM

SUBMITTER: Ho M 

PROVIDER: S-EPMC9689284 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature